Lilly’s Paying $1.1bn For Itch Advantage With Dermira’s Lebrikizumab
Executive Summary
Making a large acquisition heading into the JP Morgan Healthcare Conference for the second consecutive year, Lilly is buying Dermira and its Phase III atopic dermatitis drug lebrikizumab, setting up a competition with Sanofi’s Dupixent.
You may also be interested in...
Potential Blockbuster Lebrikizumab Among Latest Drugs Up For Decision On EU Approval
The European Medicines Agency is set to decide whether to back EU marketing approval for eight new drugs.
A Standard September Ahead Thanks To Light US FDA User Fee Calendar With Few Expedited Reviews
Twelve applications with September goal dates include six novel agents but only one breakthrough designation.
Evommune Looks To Advance Broad Pipeline Of Autoimmune Drugs
Emerging Company Profile: With experienced leadership and new financing, Evommune is developing a topical IRAK4 inhibitor for atopic dermatitis and earlier-stage systemic drugs for various conditions.